Boehringer Teams with Ochre Bio in Potential $1B Deal to Develop Regenerative Liver Drugs

Published: Apr 22, 2024 By Nick Paul Taylor

Boehringer Ingelheim_iStock, Sundry Photography

Pictured: Boehringer Ingelheim’s headquarters in Silicon Valley/iStock, Sundry Photography

Boehringer Ingelheim has struck a deal with Ochre Bio, announcing Monday an agreement potentially worth $1 billion to collaborate on treatments for liver diseases such as late-stage metabolic dysfunction-associated steatohepatitis cirrhosis.

Madrigal Pharmaceuticals recently won FDA approval for Rezdiffra (resmetirom) in metabolic dysfunction-associated steatohepatitis (MASH) and rivals are following close behind. However, Rezdiffra and other leading R&D programs target patients before they develop cirrhosis. There remains a need for therapies that can slow or reverse the progression of disease in later-stage patients, either to help them survive until a donor organ is available or eliminate the need for a transplant altogether.

Boehringer has identified Ochre as a partner that can help discover such therapies. The German…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks